Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab

A 67-year-old man with primary lung adenocarcinoma was hospitalized due to massive bilateral pleural effusion and pericardial effusion after 94 cycles of nivolumab therapy. We were unable to identify the cause of these effusions using blood tests, cytology tests, or bacterial culture of pleural effu...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawada, Ryo, Matsui, Yohei, Uchino, Junji, Okura, Naoko, Morimoto, Yoshie, Iwasaku, Masahiro, Kaneko, Yoshiko, Yamada, Tadaaki, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666223/
https://www.ncbi.nlm.nih.gov/pubmed/34092733
http://dx.doi.org/10.2169/internalmedicine.7219-21
_version_ 1784614160928079872
author Sawada, Ryo
Matsui, Yohei
Uchino, Junji
Okura, Naoko
Morimoto, Yoshie
Iwasaku, Masahiro
Kaneko, Yoshiko
Yamada, Tadaaki
Takayama, Koichi
author_facet Sawada, Ryo
Matsui, Yohei
Uchino, Junji
Okura, Naoko
Morimoto, Yoshie
Iwasaku, Masahiro
Kaneko, Yoshiko
Yamada, Tadaaki
Takayama, Koichi
author_sort Sawada, Ryo
collection PubMed
description A 67-year-old man with primary lung adenocarcinoma was hospitalized due to massive bilateral pleural effusion and pericardial effusion after 94 cycles of nivolumab therapy. We were unable to identify the cause of these effusions using blood tests, cytology tests, or bacterial culture of pleural effusion and thoracoscopy. Finally, we administrated corticosteroids, which immediately improved the fluid accumulation. This case may support the introduction of corticosteroids for late-onset pleural and pericardial effusion during immune checkpoint inhibitor (ICI) treatment. However, the safety of rechallenge of ICIs after the improvement of fluid accumulation is controversial.
format Online
Article
Text
id pubmed-8666223
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-86662232021-12-28 Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab Sawada, Ryo Matsui, Yohei Uchino, Junji Okura, Naoko Morimoto, Yoshie Iwasaku, Masahiro Kaneko, Yoshiko Yamada, Tadaaki Takayama, Koichi Intern Med Case Report A 67-year-old man with primary lung adenocarcinoma was hospitalized due to massive bilateral pleural effusion and pericardial effusion after 94 cycles of nivolumab therapy. We were unable to identify the cause of these effusions using blood tests, cytology tests, or bacterial culture of pleural effusion and thoracoscopy. Finally, we administrated corticosteroids, which immediately improved the fluid accumulation. This case may support the introduction of corticosteroids for late-onset pleural and pericardial effusion during immune checkpoint inhibitor (ICI) treatment. However, the safety of rechallenge of ICIs after the improvement of fluid accumulation is controversial. The Japanese Society of Internal Medicine 2021-06-05 2021-11-15 /pmc/articles/PMC8666223/ /pubmed/34092733 http://dx.doi.org/10.2169/internalmedicine.7219-21 Text en Copyright © 2021 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Sawada, Ryo
Matsui, Yohei
Uchino, Junji
Okura, Naoko
Morimoto, Yoshie
Iwasaku, Masahiro
Kaneko, Yoshiko
Yamada, Tadaaki
Takayama, Koichi
Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab
title Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab
title_full Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab
title_fullStr Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab
title_full_unstemmed Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab
title_short Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab
title_sort late-onset pleural and pericardial effusion as immune-related adverse events after 94 cycles of nivolumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666223/
https://www.ncbi.nlm.nih.gov/pubmed/34092733
http://dx.doi.org/10.2169/internalmedicine.7219-21
work_keys_str_mv AT sawadaryo lateonsetpleuralandpericardialeffusionasimmunerelatedadverseeventsafter94cyclesofnivolumab
AT matsuiyohei lateonsetpleuralandpericardialeffusionasimmunerelatedadverseeventsafter94cyclesofnivolumab
AT uchinojunji lateonsetpleuralandpericardialeffusionasimmunerelatedadverseeventsafter94cyclesofnivolumab
AT okuranaoko lateonsetpleuralandpericardialeffusionasimmunerelatedadverseeventsafter94cyclesofnivolumab
AT morimotoyoshie lateonsetpleuralandpericardialeffusionasimmunerelatedadverseeventsafter94cyclesofnivolumab
AT iwasakumasahiro lateonsetpleuralandpericardialeffusionasimmunerelatedadverseeventsafter94cyclesofnivolumab
AT kanekoyoshiko lateonsetpleuralandpericardialeffusionasimmunerelatedadverseeventsafter94cyclesofnivolumab
AT yamadatadaaki lateonsetpleuralandpericardialeffusionasimmunerelatedadverseeventsafter94cyclesofnivolumab
AT takayamakoichi lateonsetpleuralandpericardialeffusionasimmunerelatedadverseeventsafter94cyclesofnivolumab

Ejemplares similares